Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine the optimal dose of the combination of docetaxel and
gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with
respect to efficacy and toxicity in a phase II trial.